The study, which Dagens Medicin reports on, followed 399 adult patients with severe fatigue that could not be relieved by rest. They were randomly assigned to receive the drug fluvoxamine, the type 2 diabetes drug metformin, or a placebo.
Fluvoxamine was shown to reduce fatigue.
"This is interesting data from a well-conducted study. Fluvoxamine is a well-known drug with relatively few side effects and something that can be tested clinically in selected patients," Judith Bruchfeld, senior infectious disease physician at Karolinska University Hospital, who researches long COVID, told the newspaper.
Fluvoxamine is available in Sweden under the name Fevarin but is not subsidized.
